Treats sickle cell disease (SCD). Sold as Oxbryta. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Voxelotor (sold as Oxbryta), first approved Nov 25, 2019, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Oxbryta | Part D | $0K | -100% | 0 |
| Nov 25, 2019 | OxbrytaNDA 213137 · New molecular entity | Global Blood Theraps | 2 | Discontinued |
| Dec 17, 2021 | OxbrytaNDA 216157 · New dosage form | Global Blood Theraps | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
